Veradermics reports positive Phase 2 data for oral VDPHL01 in female hair loss

Veradermics, Incorporated (NYSE: MANE) announced positive topline results on July 15, 2026 from its open-label Phase 2 clinical trial Study '207' evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, in females with mild-to-moderate pattern hair loss.¹

The study enrolled 21 adult male and 28 adult female pattern hair loss patients to obtain proof of concept for the safety and efficacy of twelve months of treatment with VDPHL01 8.5 mg twice daily in male patients and VDPHL01 4.5 mg either once or twice daily in female patients.¹

In female participants, the average increase in non-vellus hair count was 22.7 hairs/cm² and 23.3 hairs/cm² in the once daily and twice daily treatment arms, respectively.¹ On patient-reported outcomes, 88.9% of participants in the once daily dose arm and 90.0% of participants in the twice daily dose arm achieved 'improved' or 'much improved' hair coverage on the AAIRS.¹ Investigator assessments were similar, with investigators grading 100% of once daily and 90% of twice daily participants as having improvement in hair coverage at Month 6.¹ Onset was reported as early as Month 2, when 67.2% of participants were graded by investigators as demonstrating improvement and 63.2% of participants reported improvement in hair coverage.¹

On safety, treatment with VDPHL01 was generally well tolerated through Month 6, with an overall safety profile consistent with prior studies and no treatment-related SAEs or AESIs of cardiac origin observed.¹ The most common adverse events were hypertrichosis and peripheral edema.¹

Veradermics said it is actively recruiting female participants for its Phase 2/3 trial, Study '306', with topline data anticipated in 1H 2027.¹ The company also noted it announced topline results from Study '302', a registration-directed Phase 2/3 trial in male pattern hair loss, in April, and completed enrollment in a second male Phase 3 trial, Study '304', in February, with topline results anticipated in the second half of 2026.¹